Meitheal Company Profile
What is the competitive landscape for MEITHEAL
MEITHEAL has eighty-two approved drugs.
There are four US patents protecting MEITHEAL drugs.
Summary for Meitheal
| US Patents: | 4 |
| Tradenames: | 69 |
| Ingredients: | 68 |
| NDAs: | 82 |
Drugs and US Patents for Meitheal
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meitheal | CARBOPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 077096-001 | Jun 14, 2005 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Meitheal | DOXERCALCIFEROL | doxercalciferol | INJECTABLE;INJECTION | 211670-001 | Feb 7, 2020 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Meitheal | TOPOTECAN HYDROCHLORIDE | topotecan hydrochloride | INJECTABLE;INJECTION | 201166-001 | Aug 8, 2012 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Meitheal | TIGECYCLINE | tigecycline | POWDER;INTRAVENOUS | 214020-001 | May 13, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MEITHEAL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 250 mcg/0.5 mL, 1 mL PFS | ➤ Subscribe | 2012-03-30 |
International Patents for Meitheal Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2018222656 | ⤷ Start Trial |
| South Africa | 201908325 | ⤷ Start Trial |
| New Zealand | 759953 | ⤷ Start Trial |
| Mexico | 2019014354 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Meitheal Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2768484 | SPC/GB19/067 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308(FOR NI) 20180827; UK PLGB 31626/0004 20180827 |
| 1534313 | 92923 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730 |
| 2207786 | 202340031 | Slovenia | ⤷ Start Trial | PRODUCT NAME: CEDAZURIDINE OR ITS PHARMACEUTICALLY ACCEPTEBLE SALT AND DECITABINE; NATIONAL AUTHORISATION NUMBER: EU/1/23/1756; DATE OF NATIONAL AUTHORISATION: 20230915; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 1189916 | 1190003-2.L | Sweden | ⤷ Start Trial | PRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
